Canada: Supreme Court Decision May Seriously Affect Innovator Pharmaceutical Companies

On November 3, 2006, a unanimous Supreme Court of Canada released a decision (AstraZeneca Canada Inc. v. Canada (Minister of Health) 1) that may have significant implications for innovator pharmaceutical companies. It suggests that generic manufacturers may no longer be required to address every patent listed on the Patent Register in respect of a particular drug, but only those patents that are relevant to the product cited as the Canadian reference product. The Court departed from the broad interpretation of section 5(1) of the Patented Medicines (Notice of Compliance) Regulations (Regulations) that was previously adopted by the Federal Court of Canada. Although the facts of this case are unique and it was decided under the pre-amendment Regulations, it is likely to be held out by generic manufacturers as a case of general application.


AstraZeneca began marketing omeprazole in Canada in 1989 under the brand name Losec. In 1993, Apotex filed an Abbreviated New Drug Submission (ANDS) seeking approval for a generic version of Losec omeprazole 20 mg capsules (Losec 20). Apotex’s ANDS compared its proposed product to Losec 20. In September 1996, AstraZeneca voluntarily withdrew Losec 20 from the Canadian market.

Despite the absence of Losec 20 from the market in Canada, AstraZeneca continued to list patents against it on the Patent Register maintained by the Minister of Health. In 2002 and 2003, AstraZeneca listed two additional patents on the Patent Register in relation to two Supplemental New Drug Submissions for which additional Notices of Compliance (NOCs) were issued to AstraZeneca.

In 2004, the Minister of Health granted Apotex an NOC for its generic omeprazole product even though Apotex had not delivered notices of allegation for the two additional patents. The Minister’s position was that a generic manufacturer should not be required to address patents listed for a Supplemental New Drug Submission introducing a change to a drug that was no longer marketed because the generic product could not have been compared with the drug as changed. AstraZeneca commenced a judicial review of the Minister’s decision to issue an NOC to Apotex.

The Supreme Court’s Decision

The Court agreed with Apotex that the Regulations are concerned only with patents relevant to the innovator product actually copied and not with listed patents from which a generic manufacturer could receive no benefit. In other words, relevant patents are those that the generic has relied on in making its copycat product. As AstraZeneca added the additional patents to the register after Apotex filed its ANDS and these patents were not incorporated in the Canadian reference product cited by Apotex, Apotex was not required to address them.

The particular facts of this case gave rise to the Court’s concern about innovator companies evergreening their products by "adding bells and whistles to a pioneering product … after the original patent for that pioneering patent has expired." The Court’s solution was to require Apotex to address only the "cluster of patents listed against submissions relevant to the NOC that gave rise to the comparator drug."


Recognizing the uniqueness of the facts of this case, the lower court observed that "no other brand name company has attempted to list patents in this manner in Canada, making this a novel situation." The Court found it would have been impossible for Apotex to demonstrate bioequivalence on the basis of the subsequent patents for which no product was marketed in Canada. The Court held that if AstraZeneca had marketed a version of Losec 20 under the later NOCs, and Apotex had referred to the new product for the purpose of demonstrating bioequivalence, Apotex would have been required to file a notice of allegation regarding the new patents.

As stated above, it is important to note that this case was decided under the Regulations as they existed before the recent October 5, 2006 amendments (for a discussion of these amendments please see the Food & Drug Regulatory Bulletin No. 2006-2 dated October 10, 2006 on Torys’ website). It could thus be argued that this case is of limited application to the Regulations presently in force.

Nonetheless, the Supreme Court’s narrow construction of section 5(1) may be potentially problematic for innovator pharmaceutical companies if, as it may be asserted this decision suggests, generic manufacturers no longer need to address every patent listed on the Patent Register in respect of the drug that they seek to copy.

The potential significance of this decision will depend on the facts of each particular case. We encourage a review of your company’s relevant patent portfolios to determine the impact of this case on your patent strategy and scope of protection under the Regulations.


1. 2006 SCC 49.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions